UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
INSIGHTS & ANALYSIS

Industry Intelligence

Evidence-based coverage of pharmaceutical development, regulatory affairs, and biotech innovation

Pharmaceutical11 September 2026· 12 min read

The AI revolution in drug discovery, predicting efficacy and compressing R&D timelines

Rising costs and stagnating productivity define the drug development problem that Eroom’s Law describes. The inflation-adjusted cost of bringing a new medicine to market has roughly doubled every 9 years since the 1980s, despite advances in screening and molecular biology. The…

By Megan Liu, Digital Health Reporter

Clinical Trials10 September 2026· 7 min read

Semaglutide Trial Data in Early Alzheimer Disease Shows a Signal

The primary endpoint data from the EVOKE and EVOKE Plus trials, presented at the Clinical Trials on Alzheimer's Disease (CTAD) conference in late 2024 and subsequently reported in Nature Medicine (2025), show that semaglutide (Novo Nordisk; Ozempic at 1mg subcutaneous weekly)…

By Tom Okafor, Clinical Trials Correspondent

Research9 September 2026· 8 min read

What the evidence shows about BPC-157 and tendons

More than 100 animal studies suggest BPC-157 helps tendons heal, yet as of 2026 not a single controlled human trial has tested whether it works in people. A US advisory panel has voted to loosen access all the same.

By Tom Okafor, Clinical Trials Correspondent

News25 August 2026· 8 min read

PCSK9 Inhibitors and LDL Reduction Beyond the Statin Ceiling

PCSK9 inhibitors reduce LDL-C by up to 60% on top of statins. Discover the mechanism, FOURIER and ODYSSEY OUTCOMES trial findings, and UK NICE access criteria.

By Tom Okafor, Clinical Trials Correspondent

Clinical Trials20 August 2026· 6 min read

Personalised Cancer Vaccines Cross a Threshold: What the Melanoma Result Means for Oncology

A bespoke mRNA vaccine built from a patient’s own tumour, given with Keytruda, kept high-risk melanoma from returning in a phase 3 trial. The proof of principle now shifts the hard problem to manufacturing and regulation.

By Tom Okafor, Clinical Trials Correspondent

Therapies13 August 2026· 11 min read

NICE Moves Type 2 Diabetes First-Line Therapy to SGLT2

NICE NG28 now recommends SGLT2 inhibitors as first-line therapy alongside metformin for most adults with type 2 diabetes, prioritising cardiorenal protection from diagnosis.

By Dr. Eleanor Vance, Regulatory Affairs Editor

Cancer10 August 2026· 7 min read

Modular RNA Nanoparticles Could Recast Cancer Delivery

Modular RNA nanoparticles from the University of Nottingham show breast tumour gene knockdown and influenza protection in mice — could this platform transform oncology delivery?

By Dr. Eleanor Vance, Regulatory Affairs Editor

Treatments5 August 2026· 5 min read

Long COVID Treatment: Where the Science Stands

Long COVID symptoms can drag on for years. Learn what's driving them and how treatments like H.E.L.P. apheresis are being used to address the underlying causes.

By Tom Okafor, Clinical Trials Correspondent

Research5 August 2026· 7 min read

MHRA Strengthen Valproate Restrictions for Women of Childbearing Potential

MHRA has reinforced valproate pregnancy restrictions for women of childbearing potential. Learn what the Pregnancy Prevention Programme requires of prescribers and pharmacists.

By Tom Okafor, Clinical Trials Correspondent

General29 July 2026· 6 min read

UK MHRA Agility Reform Drives Clinical Trial Innovation

The Medicines and Healthcare products Regulatory Agency (MHRA) is poised to implement the most significant overhaul of British clinical research in 20 years. Effective 28 April 2026, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 (Statutory Instrument…

By Dr. Eleanor Vance, Regulatory Affairs Editor

Research27 July 2026· 5 min read

Affidea accelerates its UK growth through strategic partnership with LIPS Healthcare

Affidea, the pan-European provider of community-based clinics and diagnostics, has announced a strategic partnership and co-investment with LIPS Healthcare, the UK's largest private consultant-led multi-specialty group.

By Priya Raghavan, Biotech & Markets Analyst

Technology27 July 2026· 9 min read

MHRA Approves Obecabtagene Autoleucel for Relapsed B-Cell Leukaemia

The MHRA has authorised obecabtagene autoleucel for relapsed B-cell leukaemia. Discover what the FELIX trial showed and what NHS access now requires.

By Tom Okafor, Clinical Trials Correspondent

Stay ahead of the curve

Subscribe to our weekly pharmaceutical intelligence digest

Browse

Popular Categories in Pharma Journal

OncologyBiotechnologyPharmaceutical CompaniesClinical ResearchRegulatory, Quality & ComplianceMedical Devices, Diagnostics & EquipmentImmunology & Inflammation
Neuroscience & CNSInfectious Disease & VaccinesRare DiseasesAnimal & Veterinary HealthIndustry Media & AssociationsCell & Gene TherapyDermatology & Aesthetics
Genomics & Precision MedicineRespiratoryCardiovascular & MetabolicContract ManufacturingConsulting, Advisory & MedCommsHaematologyOphthalmology
Private Medical Clinics (London)Recruitment & TalentDigital Health & AIFertility & IVFLab, Reagents & Research ToolsMedical & Health InsuranceWomen's Health

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy